Comparative Pharmacology
Head-to-head clinical analysis: CALDOLOR versus IBUPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALDOLOR versus IBUPROFEN.
CALDOLOR vs Ibuprofen
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing synthesis of prostaglandins involved in inflammation, pain, and fever.
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.
800 mg IV every 8 hours as a 30-minute infusion; alternatively, 400 mg IV every 6 hours. Maximum daily dose: 2400 mg.
200-800 mg orally every 6-8 hours; maximum 3200 mg/day.
None Documented
None Documented
2-4 hours (terminal half-life). Clinical context: Requires dosing every 6-8 hours for sustained effect; no accumulation with normal hepatic function.
Clinical Note
moderateIbuprofen + Gatifloxacin
"Ibuprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateIbuprofen + Rosoxacin
"Ibuprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateIbuprofen + Levofloxacin
"Ibuprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateIbuprofen + Trovafloxacin
"Ibuprofen may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is 2-4 hours; no accumulation with repeated dosing in normal renal function.
Renal (primarily as glucuronide conjugates and inactive metabolites; <10% unchanged). Biliary/fecal elimination is negligible.
Renal excretion of conjugated metabolites (about 90% as glucuronide and sulfate conjugates, <10% as unchanged drug); minor biliary/fecal elimination (<5%).
Category C
Category D/X
NSAID
NSAID